Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Bicycle Therapeutics (BCYC) Non Operating Income (2018 - 2025)

Historic Non Operating Income for Bicycle Therapeutics (BCYC) over the last 8 years, with Q3 2025 value amounting to $6.7 million.

  • Bicycle Therapeutics' Non Operating Income fell 3063.78% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.2 million, marking a year-over-year increase of 3864.95%. This contributed to the annual value of $36.1 million for FY2024, which is 23593.44% up from last year.
  • According to the latest figures from Q3 2025, Bicycle Therapeutics' Non Operating Income is $6.7 million, which was down 3063.78% from $7.4 million recorded in Q2 2025.
  • In the past 5 years, Bicycle Therapeutics' Non Operating Income ranged from a high of $14.7 million in Q4 2024 and a low of -$799000.0 during Q3 2021
  • Moreover, its 5-year median value for Non Operating Income was $2.1 million (2023), whereas its average is $3.6 million.
  • Its Non Operating Income has fluctuated over the past 5 years, first plummeted by 120972.22% in 2021, then soared by 7732222.22% in 2024.
  • Bicycle Therapeutics' Non Operating Income (Quarter) stood at -$761000.0 in 2021, then surged by 338.24% to $1.8 million in 2022, then surged by 200.94% to $5.5 million in 2023, then soared by 169.92% to $14.7 million in 2024, then plummeted by 54.8% to $6.7 million in 2025.
  • Its Non Operating Income stands at $6.7 million for Q3 2025, versus $7.4 million for Q2 2025 and $8.4 million for Q1 2025.